In the last episode we promised you a dedicated EMPA-Kidney podcast and as our Christmas gift to you, here it is!
The Filtrate:
Joel Topf
Swapnil Hiremath
Josh Waitzman
Sophia Ambruso
Priya Yenebere
With Special Guest:
Brendon Neuen, Secretariat of the SGLT2 Trialists Consortium and cool guy on Twitter.
Editor:
Sophia Ambruso
Show Notes:
Joel’s Conflict of Interest Statement. Sophia is also conflicted with Astra Zeneca and Brendon with everybody in the SGLT2i space.
Joel starts off with a history of SGLT2i
EMPA-REG Outcomes. First!
CANVAS. OMG this signal is reproducible!
CREDENCE (🎧). It works in a dedicated population at high risk of kidney disease. And in a study designed for renal end-points.
EMPA-Kidney. It works at really low GFR. And without albuminuria. And again in non-diabetics.
SGLT Inhibitors for Type 1 Diabetes: Proceed With Extreme Caution
Click to find the supplement (requires a subscription)
Who knew the supplement could be so interesting?
Differences in definition in the decreased renal function component of the composite primary outcomes.
EMPA-Kidney 40%
DAPA-Kidney 50%
CREDENCE doubling of serum Cr
Usability Testing of a Sick-Day Protocol in CKD (Pubmed)
New Guidelines for Statistical Reporting in the Journal (link, commentary on said guidelines by Frank Harrell)
The Peripheral on Amazon Prime
Unsealed the Tylenol Murders Podcast
Project Hail Mary by Andrew Weir
Lizzy McAlpine Singer Song Writer
Rachel Maddow Presents: Ultra
Twitter chaos continues. Get your Med-Mastodon handle